# Codex Review: medical_monitoring_b6_packet_freshness_20260803

Date: 2026-08-03 (CST)
Delegated-agent output: `runs/codex_medical_monitoring_b6_packet_freshness_20260803.md`

## Verdict

**Pass for this diagnostic slice; downstream B6 remains blocked.**

The new contract is narrow, pure and fail-closed. It identifies the persisted
packet as stale without rewriting it and does not turn engineering defer
outcomes into medical approval.

## Boundary Check

- Codex must confirm the delegated agent stayed inside allowed paths.
- Codex must confirm only the requested output file was written.
- No delegated agent was used. Codex changed only the new revalidation module,
  its focused tests, task-scoped context/records/review/metrics, and the new
  diagnostic artifact. The persisted B6 packet, formal package, B6/C14 gates,
  product sources and protected frontend files were not modified.

## Codex Verification

- Reopened current AGENTS, P10 ledger, B6 packet/package records and current
  B6/C14 source files.
- Focused tests: 11 passed.
- Adjacent B6/CAS/approved-input/release/real-loop contracts: 137 passed in 0.73s.
- Ruff and compileall: passed.
- Replayed 13 current file observations; the formal source manifest is complete.
- Historical packet report: stale, 15 explicit issues, candidate binding true,
  current outcome binding true, authority safe true. Replacement refresh packet:
  fresh, zero issues, all bindings true, authority safe true.
- No browser/service/provider/runtime/real project was run because this slice is
  a pre-review evidence freshness contract and B6 is still pending.
- Final self-review added a gate-top-level migration/write-flag injection test;
  it fails closed as intended.

## Delegated-Agent Output Review

Not applicable: this was Codex direct work; no Hermes dispatch or external
model session was started. The principal review risks were
checked: stale packet state, missing C14/package bindings, source-manifest drift,
candidate identity drift and accidental authority flags. The tests cover each
mutation path without repairing or inferring missing evidence.

## Residual Risk

- The fresh replacement packet proves current evidence identity only; it is not a
  formal reviewer outcome and cannot close B6.
- Aggregate/CAS replay and MY009 source-token revalidation remain unresolved,
  so C14 and all runtime/release/real-loop gates remain blocked.
